Brief: TScan Therapeutics Announces FDA Clearance Of Three Investigational NDA
23/01/2023 12:49
Jan 23 (Reuters) - TScan Therapeutics Inc TCRX.O :
* TSCAN THERAPEUTICS ANNOUNCES FDA CLEARANCE OF THREE
INVESTIGATIONAL NEW DRUG APPLICATIONS FOR THE TREATMENT OF SOLID
TUMORS
* TSCAN THERAPEUTICS INC - SCREENING PROTOCOL IS EXPECTED TO
INITIATE IN Q2 2023
* TSCAN THERAPEUTICS-ENGAGED IN STUDY START-UP
ACTIVITIES,LOOK
FORWARD TO SHARING INITIAL CLINICAL DATA FOR MOST ADVANCED TCRS
IN PROGRAM BY END OF 2023
Source text for Eikon: ID:nGNX3MSgqd
Further company coverage: TCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing